A Case Study In Bioprocess Development | A Mab

The project began with a typical industry hurdle: a high-titer cell line that produced significant product-related impurities

A dual-promoter expression vector containing both the heavy chain (HC) and light chain (LC) genes was utilized.

By using Design of Experiments (DoE), developers gain a deeper understanding of how process parameters interact.

The study follows a structured sequence typical of biopharmaceutical development: A Mab A Case Study In Bioprocess Development

The first step in the case study is establishing the . This involves determining which product quality attributes—such as glycosylation patterns, purity, aggregate levels, and potency—are critical. A CQA is a physical, chemical, biological, or microbiological property that must be within an appropriate limit to ensure desired product quality. 2.2 Process Risk Assessment (ICH Q9)

It serves as a practical, step-by-step roadmap for defining critical quality attributes (CQAs), process parameters, and design spaces.

This "flow-through" polishing step ensured that mAb-X achieved a purity level of . The project began with a typical industry hurdle:

The process begins by identifying the antibody's CQAs—physical, chemical, biological, or microbiological properties that must be within an appropriate limit to ensure safety and efficacy.

Monitored via Size Exclusion Chromatography (SEC-HPLC) and Capillary Electrophoresis (CE-SDS). Final aggregate levels were kept below 0.5%.

, specifically aggregates and fragments, which threatened the stability and efficacy of the final therapeutic. The Solution: A Quality by Design (QbD) Approach Instead of traditional trial-and-error, the team utilized a QbD framework to identify Critical Quality Attributes (CQAs): Upstream Optimization: By fine-tuning the feed strategy at manufacturing scale

Transitioning the process from a 2 L benchtop scale to a 2,000 L pilot scale introduces complex engineering challenges, primarily related to mass transfer and mixing. Scale-Up Challenges

Modern CLD processes are rapid and high-throughput, leveraging automation to screen thousands of clones. A robust platform process can accelerate this stage, but it is not without risks; the chosen clone's stability and productivity must be verified early to avoid failures later in scale-up.

A real-world challenge comes into sharp focus when a client approaches a CDMO with an initial process ill-suited for commercial manufacturing. A case study from Avid Bioservices illustrates this perfectly. A client had developed a mAb process that, at manufacturing scale, would require large chromatography columns, extended run times, and long hold steps—a recipe for high costs and low efficiency. Working under a compressed , the development team executed a "facility-fit" strategy. They performed early calculations to model column sizing and cycle times, screened high-capacity resins to reduce chromatography cycle count by over 50% , and used worst-case starting material to ensure robustness. The result? A process that lowered production costs by 25% and transferred smoothly with no unexpected issues.